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For quite some time now, a discussion has been going on in 
the world of breast cancer research concerning the optimal 
duration of hormonal therapy (HT) in hormone receptor 
(HR) positive early breast cancer. Multiple trials have tried 
providing closure to this discussion, but so far, none have 
succeeded (1).
What we do know, is that when patients are treated with 
merely tamoxifen for 5 years, disease free survival (DFS) 
can be improved by treating these patients with another 
5 years of tamoxifen or another 2.5 years with an aromatase 
inhibitor (AI), alternatively. In contrast, overall survival 
(OS) is not improved when extending therapy beyond the 
initial 5 years (2-4). It is still unclear whether extending 
treatment improves DFS or OS when patients are treated 
with an AI in the initial 5 years, though not for lack of 
trying. For example, in the MA.17R trial (5), patients 
received 3 to 5 years of tamoxifen, followed by either 
10 years of letrozole or 5 years of letrozole and 5 years 
of placebo. A small, significant difference was found for 
5-year DFS; 95% and 91%, respectively, hazard ratio (HR) 
0.66 with a 95% confidence interval (CI) of 0.48 to 0.91. 
Though, no difference was found for OS. Also, the trial 
did not included analysis for minimal clinically important 
differences (MCID), therefore, the clinical relevance 
of these statistical differences can be debated (6,7). In 
the NSABP B-42 trial (8), patients were initially treated 
with 5 years of AI or 2–3 years of tamoxifen followed by 
2–3 years of AI, and were then randomized to receive 
extended treatment for 5 years with letrozole or a placebo. 
No differences were found in DFS or OS. The IDEAL 
trial (9) compared extending therapy with letrozole for 
2.5 years or 5 years after an initial 5 years treatment with 
tamoxifen or AI. Again, no differences were found in DFS 
or OS. As evaluated by Helwick (6), the B-42 and IDEAL 
trial seem methodologically sound and the results are 
deemed comparable. 
Another recently published trial, the study of letrozole 
extension (SOLE) trial by the International Breast Cancer 
Study Group (IBCSG) (10), seeks to uncover new insights 
regarding HT. Instead of studying whether HT should 
be extended, the study focusses on different methods of 
administering extended HT; continuously or intermittently. 
It is a phase 3 clinical trial that randomized postmenopausal 
women initially treated with 4 to 6 years of HT (tamoxifen, 
AI or a combination) to continuous letrozole for 5 years 
or 9 months on and 3 months off letrozole for 4 years 
and 12 months on letrozole for the 5th year. The study 
unfortunately did not include a treatment arm in which 
therapy was not extended beyond the initial 5 years. 
Nevertheless, the concept of administering AI intermittently 
as opposed to continuously is an interesting idea. It is based 
on several preclinical trials (11-14) demonstrating that when 
HR positive tumor cells have been deprived of estrogen 
for a long period of time, sudden exposure to high doses of 
estrogen can induce cell death. 
However, when translating this concept to the study 
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design of the SOLE trial, the IBCSG did not incorporate 
an important consideration. Merely discontinuing letrozole 
for 3 months is probably not sufficient to yield adequate 
amounts of estrogen to induce cell death. The effect of 
letrozole will take about 2 weeks to completely wear off, 
and the remaining time is not enough for the women to 
produce the amounts of estrogen necessary (15,16). As 
mentioned in the commentary by Chlebowski and Pan (17), 
to reflect the preclinical study designs, the patients should 
have received additional estrogen in the period off letrozole 
to appropriately study the cytocidal effect of estrogen. 
Another curiosity in this study, as also pointed out by 
Chlebowski et al. (17), is the definition of the inclusion 
criterium “postmenopausal”. It was defined as women 
of any age either having had a bilateral oophorectomy 
or radiation castration and amenorrhea for more than 
3 months, or women of any age having biochemical evidence 
of postmenopausal status, based on serum levels of estradiol, 
follicle-stimulating hormone and luteinizing hormone. 
Yet, patients previously having received tamoxifen were 
also eligible for inclusion. Tamoxifen is known to mimic 
(biochemical) postmenopausal status, and some of these 
patients resume menses after stopping with tamoxifen (18). 
Patients who are not truly postmenopausal will have no 
benefit of letrozole (18), whether in the intermittent or 
the continuous arm. Including these patients will not 
necessarily create differences between the two arms, but 
will obscure some of the treatment effect. Moreover, 
even if it can be confirmed that all included patients who 
had undergone previous treatment with tamoxifen were 
truly postmenopausal, they will have had a shorter period 
of estrogen deprivation than patients previously treated 
with AI (9 months versus 4–6 years). Since this issue does 
not arise in the continuous arm, the observed difference 
in treatment effect between the groups might thus be 
influenced by including tamoxifen-treated patients. It 
should also be noted that 11–16% of the patients in the 
experimental arm did not stop letrozole according to 
protocol, which can contribute to concealment of any 
treatment effect, as well. 
The primary endpoint was DFS, defined as time from 
randomization to the occurrence of local, regional or 
distant relapse of breast cancer, a second cancer, or death 
without second cancer or recurrence; the results showed 
no difference in 5-year DFS between the intermittent and 
continuous group (85.8% and 87.5%, respectively, HR 1.08, 
95% CI, 0.93–1.26). As the authors already pointed out in 
the discussion section, this classical definition including 
both breast cancer related and unrelated events, might 
have obscured differences between the groups, as many 
breast cancer unrelated events, such as second non-breast 
malignancy occurred in both groups. Be that as it may, 
one of the secondary outcome measures that were studied, 
was breast cancer free interval (BCFI) and this was not 
statistically significantly different between the two groups 
either. Other secondary outcome measures that were 
studied included OS and occurrence of adverse events (AE), 
none of which were significantly different between both 
groups. 
What can be concluded from this, is that it might be 
beneficial to administer letrozole intermittently as opposed 
to continuously, but the SOLE trial is not designed to 
demonstrate this, due to its methodological flaws (19). The 
authors conclude that, at the least, intermittently is a safe 
way of administering letrozole and yields comparable results 
to continuous administration. As the follow-up of this trial 
is only 5 years, these deductions are a bit too blunt and 
longer follow-up is needed to assume safety. 
Lastly, the study included a quality of life (QoL) 
analysis, as well. This was measured in a subset of patients, 
comprising 20% of the original participants. This subset 
differed significantly from the overall group in terms of 
number of patients who were premenopausal at diagnosis 
and were previously treated with tamoxifen, instead of AI 
of a combination. The reason for choosing to perform the 
QoL analysis in a smaller group of patients is not described 
in the article. Therefore, any results cannot be projected 
onto the overall study population. At 12 months, small 
but statistically significant differences in QoL were seen 
in favor of the intermittent group, however, at 24 months, 
these differences were no longer significant. Thus, none 
of the studied outcome parameters showed statistically 
significant differences between treatment with intermittent 
or continuous letrozole. 
The regrettable characteristic that all these trials 
studying extended HT have in common, is the lack of 
translating statistical significance (when present) to clinical 
relevance. Any significant differences must be proportionate 
to the considerable side effects that occur when using an AI. 
Furthermore, the idea of extending HT is based on initial 
treatment with tamoxifen. However, AIs have proved to be 
superior to tamoxifen and current guidelines for treating 
postmenopausal patients with HR positive breast cancer 
recommend treatment with an AI. Since there has been 
no evidence as of yet to support extending treatment after 
initial treatment with an AI, maybe it is time to readjust our 
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expectations and to accept 5 years of treatment with an AI 
as sufficient. 
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